Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00568750
Show Display Options
Rank Status Study
1 Active, not recruiting Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: dasatinib

Indicates status has not been verified in more than two years